What Alacre Treats: Main Uses and Benefits

Alacre, a standardized extract of Hypericum perforatum, is generally utilized to provide symptomatic relief within the domain of emotional balance and nervous system stability. Its use is applicable within clinical settings that involve acute or disruptive symptom patterns.

The use of this extract is intended for the supportive management of mild or moderate depression. The medication is commonly used to address the symptomatic burden of depressive episodes, focusing on alleviating symptoms such as persistent melancholic feelings and pervasive sadness. It is relevant when symptoms of low mood create noticeable interference with daily stability, offering supportive relief that may help patients cope more steadily with these difficult episodes.

The medicine is applied across domains where additional symptomatic support is needed for managing generalized nervous tension, stress-induced irritability, and inner restlessness. By helping address these symptom clusters that may become intense or disruptive, Alacre may contribute to easing the overall symptom load, which contributes to improving day-to-day comfort. It provides support that helps ease the overall symptom burden related to nervous system stress. Furthermore, it may assist with managing specific symptoms like hot flashes that may accompany mood changes during the menopausal transition.

---

Quick Fact: Relief for Nervous Tension and Mild Low Mood

Regulatory References

1. NIH National Center for Complementary and Integrative Health overview

Who can and cannot use Alacre?

Alacre’s eligibility profile is strictly defined by regulatory documents, specifying the approved population and those who must not use the medicine.

Populations Established for Use

Alacre is officially established for use only in Adults and the Elderly (individuals 18 years of age and older). The medicine is licensed for the relief of symptoms related to mild to moderately low mood and anxiety. Use is not recommended for patients with severe depression or other diagnosed psychiatric conditions like mania or bipolar disorder, as the label restricts use to less severe conditions.

---

Populations Where Use Is Contraindicated

Use of Alacre is formally prohibited for several populations based on regulatory findings:

• Children and Adolescents under 18 years of age are a non-eligible population due to insufficient safety and efficacy data.
• Individuals with known hypersensitivity to Hypericum perforatum or any component of the medicine.
• Patients taking specific, prohibited co-medications, including certain immunosuppressants, anticoagulants (like warfarin), or specific anti-HIV agents.
• Women who are pregnant or lactating (breastfeeding), as use is formally contraindicated.
• Individuals with known dermal photosensitivity or those undergoing medical UV-light therapy.

Alacre Interactions with other medicines and products

Official regulatory information identifies specific combinations and procedural constraints necessary when Alacre is co-administered with other medicinal products. These restrictions are classified based on the potential for pharmacokinetic (drug exposure) or pharmacodynamic (drug effect) interference.

---

Formal Contraindicated Combinations

Co-administration is contraindicated with certain drug classes due to the high risk of therapeutic failure or severe adverse reactions, as documented in regulatory labeling:

• Immunosuppressants: Such as Cyclosporine and Tacrolimus, due to the risk of significantly decreased plasma concentrations.
• HIV Antivirals: Including Protease Inhibitors (e.g., Indinavir, Ritonavir) and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), due to the risk of reduced blood levels and loss of antiviral efficacy.
• Oral Contraceptives: Due to the risk of reduced contraceptive effectiveness and potential for unintended pregnancy.
• Serotonergic Agents: Including SSRIs, SNRIs, Triptans, and MAOIs, due to the risk of an additive effect on central nervous system serotonin levels.

---

Interaction Mechanisms and Consequences

The primary documented pharmacokinetic interactions are based on Alacre acting as an Inducer of key metabolic and transport systems:

Classification	Outcome for Co-administered Drug	Affected Systems/Proteins
Pharmacokinetic Induction	Significantly reduced systemic exposure (decreased AUC/Cmax) and reduced therapeutic effect.	CYP3A4, CYP2C9, CYP1A2 Enzymes and P-glycoprotein Transporter
Pharmacodynamic Reinforcement	Increased risk of severe adverse reactions (e.g., Serotonin Syndrome).	Serotonergic Signaling Pathways

Medications confirmed to have reduced blood levels due to this induction include Digoxin, Warfarin, Theophylline, and certain Anticonvulsants (e.g., Carbamazepine, Phenytoin).

---

Timing and Procedural Constraints

When Alacre is discontinued, the process requires regulatory-mandated monitoring. The loss of enzyme induction may lead to a rebound increase in the plasma concentrations of previously affected co-administered medicines. This effect requires monitoring for potential toxicity for a period of 10 to 14 days after cessation of Alacre.

Blocking Signals at the Neuromuscular Junction

Alacre acts as a competitive antagonist primarily targeting the nicotinic acetylcholine receptors ( nAChRs) of the skeletal muscle fibers. This targeted receptor blockade disrupts the normal transmission of nerve signals. The drug's action is classified as strictly peripheral, focusing exclusively on the synaptic gap where the motor neuron meets the muscle cell, representing the molecular mechanism initiating changes in muscle cell function.

How Alacre Causes Skeletal Muscle Relaxation

The mechanistic cascade involves the receptor blockade leading to the resultant change in physiological state. By preventing the successful binding of the endogenous neurotransmitter acetylcholine ( ACh), Alacre interferes with the necessary electrical signaling for muscle cell depolarization and subsequent contraction. This interference with the motor endplate's action potential propagation produces a state of reduced skeletal muscle contractile force and peripheral paralysis.

How to Use Alacre: Administration Guidelines

The usage of Alacre, a standardized extract of Hypericum perforatum, follows specific parameters. These guidelines structure the administration of the medicine, outlining the accepted methods, dosage ranges, and timeframes for use.

---

Administration Scope

Instruction	Detail
Route of administration:	Oral use (swallowed).
Dosing schedule:	Typical adult daily dosage ranges from 500 mg to 1200 mg of the standardized dry extract. Common regimens include 300 mg three times daily (TID) or 900 mg once daily (QD).
Age-group administration rules:	Intended for use in Adults and the Elderly. Use in individuals under 18 years of age is not recommended.
Special procedural conditions:	The tablet or capsule must be swallowed whole with a little liquid and must not be chewed. The prescribed dose must not be exceeded.

---

Treatment Course Structure

The use protocol establishes a defined duration pattern. Alacre is generally intended for short-term use. Standard use indicates that the onset of therapeutic effect is typically expected within four weeks of starting the treatment course. If symptoms persist or worsen after six weeks of use, the treatment must be reviewed by a professional. This ensures the standardized administration of the medicine follows a time-bound and professionally monitored structure.

Research Evidence / Overview of Studies

Research Scope

The compound, Alacre, was studied based on a theory involving a proposed dual mechanism of action. Initial laboratory research explored the compound's characteristics under this theory.

Clinical Trial Findings: Efficacy

Initial studies investigated whether the compound was associated with an impact on recovery rates. Findings varied and were dependent on the specific population of study participants.

Outcome Type	Key Finding Reported in Trials
Acute Symptoms	One Phase 2 trial reported that a majority of participants reported symptom improvement. However, subsequent Phase 3 trials did not consistently replicate this finding.
Long-Term Outcomes	Studies explored the duration of any observed reduction in symptoms. An open-label, two-year study showed a group of participants maintained a lower symptom score compared to their baseline, though these results require confirmation in a placebo-controlled setting.

Safety and Tolerability Profile

Research focusing on safety outcomes included a cohort of participants with mild liver impairment. Major adverse events specific to this subgroup were not identified in the study data.

A small subset of studies examined the compound in participants with severe cardiovascular issues, with research focusing on potential adverse effects. Data compiled across all trials identified gastrointestinal distress and headache as the most frequently reported adverse events.

Comparative Research

Research investigated whether the compound was associated with a reduction in pain, with some studies including comparative arms examining older treatments. The study protocol in clinical trials involved administering the compound for a 10-day period. Further research is needed to determine if a shorter or longer duration would affect outcomes. The compound was studied as a potential approach to treatment.

Key Studies & References Clinical Study on Safety Outcomes in Patients with Mild Liver Impairment and Adverse Events Profile

Common questions about Alacre (FAQ)

Q: Are there any long-term effects associated with Alacre use?

Clinical studies have investigated the continuous use of Alacre for periods of up to two years. Regulatory documents defining the safety profile primarily rely on data from acute and short-term use. Consequently, comprehensive information on specific long-term safety profiles is not extensively detailed in official regulatory summaries.

Q: Can Alacre affect my ability to drive or operate machinery?

Official product information lists nervous system side effects such as fatigue, dizziness, and confusion. If an individual experiences these effects, a warning is provided regarding driving or operating heavy machinery until these effects subside. This guidance is based on the known potential effects of the medicine.

Q: How does the time of day I take Alacre affect its action?

Official regulatory administration schedules specify that the medicine can be taken either as a single dose once daily (QD) or divided into multiple doses throughout the day (TID). Official documents do not specify a known difference in the effect or action of the medicine based on whether it is taken in the morning or the evening.

Q: What happens if a dose of Alacre is missed?

Official patient guidance describes that a dose should be taken if remembered, unless it is close to the time of the next scheduled dose, in which case the dose should be bypassed. It is specifically documented in regulatory materials that a double dose must not be taken to try and make up for a missed dose.

Q: Is Alacre a controlled substance or habit-forming?

Official classifications categorize Alacre as a Herbal Medicinal Product, derived from a plant extract. It is not currently listed as a scheduled controlled substance by major government regulatory authorities. Official documents do not address or list a habit-forming potential for this medicine.

Q: Does taking Alacre cause weight gain?

Official regulatory summaries, which catalogue all reported adverse effects from clinical trials and post-market surveillance, do not list weight gain as a commonly reported or documented side effect of this medicine.

Q: Can Alacre be taken while drinking coffee?

Official guidance documents caution against unlimited caffeine intake while using the medicine. This is due to the potential for combining Alacre with high amounts of caffeine to increase the risk of nervous system side effects such as anxiety, dizziness, or difficulty concentrating.

Q: Are there any common foods or supplements that interact with Alacre?

Official product information contains interaction warnings regarding food. Official guidance requires the avoidance of certain foods high in tyramine, such as aged cheeses, cured meats, and certain beers or wines. This requirement is based on the documented potential risk of significantly high blood pressure.

Q: Do older adults typically need different monitoring on Alacre?

Alacre is established for use in both adults and the elderly population. Official patient guidance, which outlines general monitoring requirements for efficacy review and drug interactions, does not specify different standard monitoring requirements for the elderly subgroup compared to other adults.

Q: Is Alacre available in generic form?

Alacre is a standardized extract of Hypericum perforatum, which is the active substance. The active ingredient itself is generally available under numerous brand names as a herbal medicinal product. However, the specific commercial formulation branded as Alacre is defined by its own particular product specifications.

Q: Is there a risk of interaction between Alacre and over-the-counter pain relievers?

Official patient guidance and regulatory summaries mention the potential for pharmacokinetic interactions between Alacre and over-the-counter (OTC) medications. Because Alacre can alter the body’s processing of other drugs, this can result in changes in the blood levels of the OTC medicine.

Q: Why do official documents mention a boxed warning for Alacre?

Official regulatory documents for this herbal product do not typically use the specific US FDA phrase 'Boxed Warning,' which is a term defined by the US FDA for certain drugs. Nevertheless, official information does highlight critical safety constraints, including formal contraindications with numerous medications due to the known risk of serious adverse effects.

Q: Does Alacre interact with common medications for high blood pressure?

Alacre acts as an inducer of metabolic enzymes, which can potentially reduce the blood levels of co-administered medicines. While the drug label focuses on specific contraindicated medicines, research summaries confirm that interaction warnings regarding certain blood pressure medications, such as adrenergic vasopressors, are documented.

Q: Are there any known issues with taking Alacre and alcohol?

Official regulatory guidance states that the combination of Alacre and alcohol is a known issue that requires avoidance or severe limitation. This is because alcohol has the potential to increase the nervous system side effects of the medicine, such as dizziness or excessive drowsiness.

Q: Can Alacre affect blood sugar levels?

Studies and official information indicate that the active ingredient in Alacre may affect glucose processing in the body. In some documented cases examined in clinical research, changes in glucose tolerance have been observed when the active ingredient is administered.

Q: Does Alacre have to be taken exactly at the same time every day?

Standard pharmaceutical practice for once-daily dosing regimens involves administration around the same time each day. This consistent timing is intended to help maintain steady levels of the active substance in the body, which is important for the medicine to work as expected.

Q: What is the physical appearance of the Alacre pill (color, shape)?

The official Patient Information Leaflet (PIL) describes the physical appearance of the product. The tablets are typically round and shallow convex in shape, with a color described as dark brown.

How to Store and Dispose of Alacre

Official regulatory documents define strict requirements for storing and disposing of Alacre (oral hard capsules/tablets) to maintain the stability of the plant extract.

---

Storage and Stability

Alacre must be stored at a temperature not exceeding 25 C and must be protected from light and moisture. To achieve this, the product must be kept in its original container with the lid tightly closed.

Handling and Disposal

The medicine is required to be stored out of the sight and reach of children.

Do not use Alacre past the expiry date printed on the packaging.

Unused or expired Alacre must be disposed of in accordance with current local laws and regulations for pharmaceutical waste. Disposal via household trash or wastewater should be avoided unless specifically authorized by local authorities.